Is Molecular Pharmacology (USA), Ltd. (MLPH) a Buy, Sell, or Hold?
OTC : MLPH
Molecular Pharmacology (USA), Ltd.
$0.0202 USD
$0 (0.0%)
- Volume
- 125K
- Average Volume
- 19.97K
- Market Capitalization
- $403.82K
- P/E Ratio
- -336.52
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.49
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
Jeffrey David Edwards
Biotechnology
Healthcare
MLPH
1
AU
USD
Liquidity Metrics
0.00
0.00
0.00
0.00
0.00
Sales & Valuation
-$
0.00
0.00
0.00
0.00
Profitability
$0
-$5520
0.00%
0.00%
0.00%
0.00%
P/E Metrics
-336.52
-3.37
-3.37
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-636.69
1/9
-$2.1M
$8844.0
$2.11M
-$6720.0
Key Metrics (TTM)
$403.82K
0.00
-336.52
0.00
0.00%
0.00%
-0.30%
0.00%
0 days
Company Executives
| Name | Title |
|---|---|
| Jeffrey D. Edwards | Chief Executive Officer, President, Chief Financial Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Molecular Pharmacology (USA), Ltd. (OTC:MLPH) Stock
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and m ... arket a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Frequently Asked Questions
-
What is the current Molecular Pharmacology (USA), Ltd. (MLPH) stock price?
-
Molecular Pharmacology (USA), Ltd.(OTC:MLPH) stock price is $0.0202 in the last trading session. During the trading session, MLPH stock reached the peak price of $0.485 while $0.0002 was the lowest point it dropped to. The percentage change in MLPH stock occurred in the recent session was 0.0% while the dollar amount for the price change in MLPH stock was $0.
-
MLPH's industry and sector of operation?
-
The OTC listed MLPH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MLPH?
-
Jeffrey D. Edwards | Chief Executive Officer, President, Chief Financial Officer & Director
|
|
|
| -
How many employees does MLPH have?
-
Number of MLPH employees currently stands at 1. MLPH operates from Drug Discovery Centre, Perth, WA 6007, AU.
-
Link for MLPH official website?
-
Official Website of MLPH is: https://molpharm.aspetjournals.org/
-
How do I contact MLPH?
-
MLPH could be contacted at phone #61 8 9443 3011 and can also be accessed through its website. MLPH operates from Drug Discovery Centre, Perth, WA 6007, AU.
-
How many shares of MLPH are traded daily?
-
The average number of MLPH shares traded daily for last 3 months was 19.97K.
-
What is the market cap of MLPH currently?
-
The market value of MLPH currently stands at $403.82K with its latest stock price at $0.0202